CO5450243A1 - Derivados de 2,6-quinolinilo y 2,6-naftilo, procesos para su preparacion - Google Patents
Derivados de 2,6-quinolinilo y 2,6-naftilo, procesos para su preparacionInfo
- Publication number
- CO5450243A1 CO5450243A1 CO03035403A CO03035403A CO5450243A1 CO 5450243 A1 CO5450243 A1 CO 5450243A1 CO 03035403 A CO03035403 A CO 03035403A CO 03035403 A CO03035403 A CO 03035403A CO 5450243 A1 CO5450243 A1 CO 5450243A1
- Authority
- CO
- Colombia
- Prior art keywords
- derivative
- alkyl
- formula
- heterocycle
- cycloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/63—Esters of sulfonic acids
- C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
- C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Quinoline Compounds (AREA)
Abstract
Compuesto que tiene la fórmula l o una de sus sales farmacéuticamente aceptables, <EMI FILE="03035403_1" ID="1" IMF=JPEG >En la cualX es N o CH;R1 es cicloalquilo, arilo, heterociclo, aralquilo, heterociclo-alquilo, o un oxi-derivado, o un grupo de fórmula: <EMI FILE="03035403_2" ID="2" IMF=JPEG >R2 es -NR4R5, -OR4 o -C(=O)NR5R6;R3 es tetrazol, -CN, -CH2OH o -CO-R7R4 es H, -G1-R8, o un grupo de fórmula: <EMI FILE="03035403_3" ID="3" IMF=JPEG >R5 es H, C1-4-alquilo; o -NR4R5 representa un heterociclo o -N=CR9R10; R6 es arilo, heterociclo, cicloalquilo o aralquilo;R7 es hidroxi, amino, hidroxilamino, un oxi-derivado o un amino-derivado;G1 es CO, CH2, SO2;R8 es arilo, heterociclo, cicloalquilo, aralquilo o -NH-arilo.R9 es arilo; yR10 es éter;Con la condición de que cuando x es CH, R1 es cicloalquilo o un oxi-derivado de fórmula -O-Ra en la cual Ra es C1-6-alquilo, un fenilo opcionalmente sustituido o trifluorometilo R2 es -NR4R5, R3 es CO-R7, R4 es H o G1-R8, R5 es H, C1-4-alquilo, G1 es CO, CH2, SO2, R8 es un grupo fenilo opcionalmente sustituido, cicloalquilo o -NH-fenilo (un opcionalmente sustituido), entonces R7 no es un oxi-derivado de fórmula -O-CHRbRc en la cual Rb es H, C1-6- alquilo o un fenilo opcionalmente sustituido y RC es un fenilo opcionalmente sustituido, o un amino-derivado de fórmula -NRd-CHRbRc en la cual Rb y RC tienen las mismas definiciones que se han descrito anteriormente, y Rd es H o C1-6-alquilo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02009746 | 2002-04-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5450243A1 true CO5450243A1 (es) | 2004-10-29 |
Family
ID=29286106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO03035403A CO5450243A1 (es) | 2002-04-30 | 2003-04-29 | Derivados de 2,6-quinolinilo y 2,6-naftilo, procesos para su preparacion |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US7638630B2 (es) |
| EP (2) | EP1870402A1 (es) |
| JP (1) | JP2005535583A (es) |
| KR (1) | KR100841165B1 (es) |
| CN (2) | CN101200450A (es) |
| AR (1) | AR039341A1 (es) |
| AT (1) | ATE384699T1 (es) |
| AU (1) | AU2003232472B2 (es) |
| BR (1) | BR0309719A (es) |
| CA (1) | CA2484954C (es) |
| CO (1) | CO5450243A1 (es) |
| CU (1) | CU23415B7 (es) |
| DE (1) | DE60318839T2 (es) |
| ES (1) | ES2298543T3 (es) |
| IL (1) | IL164516A0 (es) |
| MX (1) | MXPA04010673A (es) |
| MY (1) | MY135218A (es) |
| NO (1) | NO20045234L (es) |
| NZ (1) | NZ536180A (es) |
| PL (1) | PL373763A1 (es) |
| RU (1) | RU2315041C2 (es) |
| TW (2) | TWI268278B (es) |
| WO (1) | WO2003093237A1 (es) |
| ZA (1) | ZA200408447B (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2315041C2 (ru) * | 2002-04-30 | 2008-01-20 | ЮСиБи, С.А. | Производные 2,6-хинолинила и 2,6-нафтила, фармацевтические композиции на их основе, их применение в качестве ингибиторов vla-4 и промежуточные соединения |
| US7153889B2 (en) | 2002-11-12 | 2006-12-26 | Abbott Laboratories | Bicyclic-substituted amines as histamine-3 receptor ligands |
| CN101386600B (zh) | 2003-02-20 | 2011-07-06 | 味之素株式会社 | 具有喹唑二酮骨架的苯丙氨酸衍生物的制造方法及制造中间体 |
| US7145005B2 (en) | 2004-05-12 | 2006-12-05 | Abbott Laboratories | 2-(6-{2-[(2R)-2-Methyl-1-pyrrolidin-1-yl]-ethyl}-2-naphthalen-2-yl)-2H-pyridazin-3-one salts and their preparation |
| US7098222B2 (en) | 2004-05-12 | 2006-08-29 | Abbott Laboratories | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents |
| US7205316B2 (en) | 2004-05-12 | 2007-04-17 | Abbott Laboratories | Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands |
| EA013080B1 (ru) * | 2005-06-09 | 2010-02-26 | Юсб Фарма С.А. | 2,6-хинолинильные производные, способы их получения и их применение |
| KR20090086539A (ko) | 2006-11-14 | 2009-08-13 | 산텐 세이야꾸 가부시키가이샤 | (치환 페닐 또는 치환 복소환) 카르보닐옥시 저급 알킬기와 에스테르 구조를 도입한 페닐기를 치환기로서 갖는 신규 1,2-디히드로퀴놀린 유도체 |
| WO2008125215A1 (en) * | 2007-04-12 | 2008-10-23 | Ucb Pharma, S.A. | Bicyclic and heterobicyclic derivatives, processes for preparing them and their uses |
| WO2008125210A1 (en) * | 2007-04-12 | 2008-10-23 | Ucb Pharma, S.A. | Quinoline and naphthalene derivatives, processes for their preparation and their use in treatment of inflammatory diseases |
| WO2008138592A1 (en) * | 2007-05-14 | 2008-11-20 | Ucb Pharma, S.A. | Bicyclic and heterobicyclic derivatives, processes for preparing them and their uses |
| WO2008138615A1 (en) * | 2007-05-16 | 2008-11-20 | Ucb Pharma, S.A. | Bicyclic and heterobicyclic derivatives, processes for preparing them and their uses |
| KR20100098683A (ko) * | 2007-12-12 | 2010-09-08 | 아스트라제네카 아베 | 펩티딜 니트릴, 및 디펩티딜 펩티다제 ｉ 억제제로서의 그의 용도 |
| EP2085407A1 (en) | 2008-02-04 | 2009-08-05 | Sahltech I Göteborg AB | Treatment of idiopathic thrombocytopenic purpura |
| AU2009247250B2 (en) * | 2008-05-12 | 2014-04-10 | Ayumi Pharmaceutical Corporation | Glucocorticoid receptor agonist composed of 2,2,4-trimethyl-6-phenyl-1,2-dihydroquinoline derivatives having substituted oxy group |
| WO2011020874A1 (en) | 2009-08-20 | 2011-02-24 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy |
| US20150368213A1 (en) * | 2014-06-20 | 2015-12-24 | The University of Montana, Missoula, MT | Novel Inhibitors of System Xc- |
| CN115925679A (zh) * | 2014-12-24 | 2023-04-07 | 株式会社Lg化学 | 作为gpr120激动剂的联芳基衍生物 |
| AU2019373245C1 (en) | 2018-10-30 | 2022-10-27 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4β7 integrin |
| KR102630416B1 (ko) | 2018-10-30 | 2024-02-01 | 길리애드 사이언시즈, 인코포레이티드 | 알파4베타7 인테그린 억제제로서의 퀴놀린 유도체 |
| WO2020092394A1 (en) | 2018-10-30 | 2020-05-07 | Gilead Sciences, Inc. | Imidazopyridine derivatives as alpha4beta7 integrin inhibitors |
| KR102652797B1 (ko) | 2018-10-30 | 2024-04-02 | 길리애드 사이언시즈, 인코포레이티드 | 알파4베타7 인테그린의 억제를 위한 화합물 |
| JP7491996B2 (ja) | 2019-08-14 | 2024-05-28 | ギリアード サイエンシーズ， インコーポレイテッド | α４β７インテグリンの阻害のための化合物 |
| EP4284947A1 (en) | 2021-01-29 | 2023-12-06 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods of assessing the risk of developing progressive multifocal leukoencephalopathy in patients treated with vla-4 antagonists |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2920741B2 (ja) * | 1994-12-14 | 1999-07-19 | 参天製薬株式会社 | 新規１，３−ジアルキルウレア誘導体 |
| WO1996018606A1 (fr) * | 1994-12-14 | 1996-06-20 | Santen Pharmaceutical Co., Ltd. | Nouveaux derives 1,3-dialkyluree |
| JPH0987291A (ja) * | 1995-09-26 | 1997-03-31 | Wakamoto Pharmaceut Co Ltd | 新規なアラニン誘導体 |
| EP0977989A1 (en) | 1997-02-04 | 2000-02-09 | Trega Biosciences, Inc. | 4-substituted-quinoline derivatives and 4-substitute-quinoline combinatorial libraries |
| CN100369888C (zh) * | 1997-08-22 | 2008-02-20 | 霍夫曼-拉罗奇有限公司 | 芳酰基苯丙氨酸衍生物 |
| DK1114028T3 (da) * | 1998-08-26 | 2007-04-30 | Aventis Pharma Ltd | Azabicykliske forbindelser, der modulerer inhibering af celleadhæsion |
| NZ515284A (en) | 1999-04-28 | 2004-12-24 | Dr | Substituted bicyclic heterocycles, process for their preparation and their use as antiobesity and hypocholesterolemic agents |
| US6280442B1 (en) * | 1999-09-01 | 2001-08-28 | Sdgi Holdings, Inc. | Multi-axial bone screw assembly |
| US6399599B1 (en) * | 1999-10-13 | 2002-06-04 | Novartis Ag | Substituted 2-oxo-1,4-diazacycloalkanes |
| RU2315041C2 (ru) * | 2002-04-30 | 2008-01-20 | ЮСиБи, С.А. | Производные 2,6-хинолинила и 2,6-нафтила, фармацевтические композиции на их основе, их применение в качестве ингибиторов vla-4 и промежуточные соединения |
| EA013080B1 (ru) | 2005-06-09 | 2010-02-26 | Юсб Фарма С.А. | 2,6-хинолинильные производные, способы их получения и их применение |
-
2003
- 2003-04-15 RU RU2004135304/04A patent/RU2315041C2/ru not_active IP Right Cessation
- 2003-04-15 NZ NZ536180A patent/NZ536180A/en not_active IP Right Cessation
- 2003-04-15 AU AU2003232472A patent/AU2003232472B2/en not_active Ceased
- 2003-04-15 MX MXPA04010673A patent/MXPA04010673A/es active IP Right Grant
- 2003-04-15 KR KR1020047017498A patent/KR100841165B1/ko not_active IP Right Cessation
- 2003-04-15 WO PCT/EP2003/003909 patent/WO2003093237A1/en active IP Right Grant
- 2003-04-15 CA CA2484954A patent/CA2484954C/en not_active Expired - Fee Related
- 2003-04-15 PL PL03373763A patent/PL373763A1/xx not_active Application Discontinuation
- 2003-04-15 AT AT03747411T patent/ATE384699T1/de not_active IP Right Cessation
- 2003-04-15 DE DE60318839T patent/DE60318839T2/de not_active Expired - Lifetime
- 2003-04-15 BR BR0309719-6A patent/BR0309719A/pt not_active IP Right Cessation
- 2003-04-15 EP EP07017712A patent/EP1870402A1/en not_active Withdrawn
- 2003-04-15 CN CNA2007101934884A patent/CN101200450A/zh active Pending
- 2003-04-15 CN CNA038097907A patent/CN1649842A/zh active Pending
- 2003-04-15 ES ES03747411T patent/ES2298543T3/es not_active Expired - Lifetime
- 2003-04-15 EP EP03747411A patent/EP1501801B1/en not_active Expired - Lifetime
- 2003-04-15 JP JP2004501376A patent/JP2005535583A/ja not_active Ceased
- 2003-04-15 US US10/513,347 patent/US7638630B2/en not_active Expired - Fee Related
- 2003-04-23 AR ARP030101389A patent/AR039341A1/es unknown
- 2003-04-25 TW TW094147669A patent/TWI268278B/zh active
- 2003-04-25 TW TW092109709A patent/TWI267508B/zh not_active IP Right Cessation
- 2003-04-29 MY MYPI20031612A patent/MY135218A/en unknown
- 2003-04-29 CO CO03035403A patent/CO5450243A1/es not_active Application Discontinuation
-
2004
- 2004-10-12 IL IL16451604A patent/IL164516A0/xx unknown
- 2004-10-19 ZA ZA200408447A patent/ZA200408447B/en unknown
- 2004-11-01 CU CU20040252A patent/CU23415B7/es not_active IP Right Cessation
- 2004-11-29 NO NO20045234A patent/NO20045234L/no unknown
-
2009
- 2009-10-23 US US12/604,959 patent/US20100105681A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5450243A1 (es) | Derivados de 2,6-quinolinilo y 2,6-naftilo, procesos para su preparacion | |
| AR109033A2 (es) | Derivados de 1,4-benzotiepina-1,1-dióxido sustituidos con radicales bencilo, productos farmacéuticos que comprenden estos compuestos y su uso | |
| RS52931B (en) | VIRAL POLYMERASE INHIBITORS | |
| TR200000447T2 (tr) | 5-Alkil-2-arilaminofenilasetik asitler ve türevleri. | |
| CO5700820A2 (es) | Derivados de dioxan-2-alquilcarbamatos, su preparacion y su aplicacion en terapeutica | |
| RS50540B (sr) | Substituisani piridinil i pirimidinil derivati kao modulatori metabolizma i lečenje poremećaja proisteklih iz toga | |
| RS52711B (en) | INDOLAMIN 2,3-DIOXYGENASE MODULATORS AND PROCEDURES FOR USING THE SAME | |
| AR063015A1 (es) | Derivados de quinazolinona 5-sustituida y composiciones que los comprenden y metodos para utilizarlos en el tratamiento del cancer | |
| AR082825A2 (es) | Inhibidores heterociclicos nitrogenados de mek, composiciones farmaceuticas que los contienen, metodos para prepararlos y uso de los mismos para el tratamiento de trastornos hiperproliferativos o inflamatorios | |
| EA200600381A1 (ru) | Метансульфонат этилового эфира 3-[(2-{[4-(гексилоксикарбониламиноиминометил)фениламино]метил}-1-метил-1н-бензимидазол-5-карбонил)пиридин-2-иламино]пропионовой кислоты и его применение в качестве лекарственного средства | |
| DE60300824D1 (de) | Laserprojektionssystem | |
| DE602004016353D1 (de) | Dentalzusammensetzungen und verfahren mit arylsulfinatsalzen | |
| EA200400987A1 (ru) | Трипептиды, несущие простой гидроксипролиновый эфир замещённого хинолина, предназначенные для ингибирования протеазы ns3 (гепатит c) | |
| DK1505998T3 (da) | Forbedret anvendelse af hop-syrer som antimikrobielle midler | |
| DE602004012448D1 (de) | Morpholinylhaltige benzimidazole als inhibitoren der replikation von respiratory syncytial virus | |
| AR041256A1 (es) | Indoles sustituidos en posicion 2,4 y su uso como moduladores de 5-ht6 | |
| NO20031185D0 (no) | Fusjonsprotein fra antistoff-cytokin-cytokininhibitor (selektokin) for anvendelse som målspesifikt prolegemiddel | |
| ATE251117T1 (de) | Neue aminobenzophenone | |
| UY28375A1 (es) | Agente terapéuticos | |
| AR014714A1 (es) | Sales de cetoacidos y derivados de aminas, y su utilizacion para la preparacion de medicamentos | |
| ES2571834T3 (es) | Alquilsulfonamida quinolinas | |
| EA200401482A1 (ru) | Ненуклезидные ингибиторы обратной транскриптазы | |
| NO20090332L (no) | 4-amino-3-arylamino-6-arylpyrazol[3,4-D]pyrimidinderivater, fremgangsmater for deres fremstilling og dere anvendelse som antivirale midler | |
| EA200501900A1 (ru) | Новый способ синтеза периндоприла и его фармацевтически приемлемых солей | |
| EA200600898A1 (ru) | Новый способ синтеза периндоприла и его фармацевтически приемлемых солей |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Application granted | ||
| FD | Application lapsed |